Project Grant 1548692

This $275,000 Small Business Technology Transfer (STTR) Phase I grant from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships program) was awarded to Oncoblaze LLC to develop a novel device for targeted delivery of chemotherapy agents to tissue surrounding surgically removed tumors. The project aims to address the issue of tumor recurrence after cancer surgery, which affects 30-40% of patients for certain cancers. The device uses an infrared laser to heat...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) award of $274,947 to Lattice Therapeutics Inc. supports the development of a customizable, next-generation RNA delivery particle. The project aims to validate the ability of an engineerable protein nanoparticle platform to efficiently and specifically deliver RNA cargoes to target cancer cells. Key objectives include in vitro evaluation of RNA...

Federal Grant Award Summary Glow Therapeutics Inc. received a $305,000 Small Business Innovation Research (SBIR) Phase I Project Grant from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) to develop a light-activatable nanoplatform for targeted delivery of photodynamic therapy (PDT) and chemotherapy to peritoneal metastasis. The award, issued June 15, 2025, with completion targeted for May 31, 2026, supports translation of a...

This National Science Foundation (NSF) SBIR Phase I Project Grant awarded to Eascra Biotech, Inc. is focused on developing and advancing regulatory pathways for space-made Janus Base Nanoparticles (JBNPs) as an innovative drug delivery system for treating solid tumors. The $274,990 award, granted on December 15, 2024, aims to demonstrate the comparability of space-manufactured JBNPs to earth-made counterparts, with the goal of revolutionizing cancer treatment by providing a versatile and more...

Superior Nano LLC received a $512,000 National Science Foundation Project Grant to develop dense nanolipid fluid systems for delivering drugs with poor bioavailability. The NSF funding supports research from June 2022 to May 2023 under the Technology, Innovation, and Partnerships program. This award will allow Superior Nano to advance scientific understanding of surfactant-lipid-water systems and create new knowledge applicable to manufacturing drug nanoparticles using twin-screw extrusion. By...

Federal Project Grant Summary Piezo Therapeutics, Inc. received a $304,742 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) to develop a novel intradermal delivery platform for nucleic acid vaccines. The company will design and optimize a handheld electroporation pen device that delivers naked nucleic acid vaccines directly to immune cells without requiring lipid nanoparticles...

This Project Grant award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Targeting Systems to develop a novel intramuscular gene delivery platform capable of sustained expression and endogenous secretion of bispecific natural killer cell engager (BIKE) therapeutics to treat solid tumors like hepatocellular carcinoma. The platform aims to deliver BIKEs in a less invasive manner than current immunotherapies,...

This STTR Phase I project, funded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), aims to advance the development and evaluation of a hand-held induction heater device for treating pancreatic and prostate cancer using magnetic fluid hyperthermia (MFH) technology. The project, awarded to Ihnnova LLC, a small business located in Guánica, Puerto Rico, will receive $275,000 in funding over the period of October 1, 2024 to...

Karios Technologies LLC, a for-profit organization, received a $274,954 SBIR Phase I grant from the National Science Foundation (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a novel, ready-to-use, large volume delivery system for in situ forming biomaterials. The biomaterials are intended to serve as tissue sealants, scar tissue reducers, and vehicles for drug or cell delivery during surgical procedures. The project aims to transfer a proprietary biomaterial...

This SBIR Phase I project, awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), aims to develop a method to turn on cancer immunotherapies only at the site of disease. The $275,000 award will support Synsorybio, Inc., a for-profit organization, in creating protein switches that activate immunotherapies in response to disease signals, rather than indiscriminately throughout the body. This approach seeks to improve the...